Home  »  Business   »  Here’s Why ACADIA Pharmaceuticals Inc. (NASD...

Here’s Why ACADIA Pharmaceuticals Inc. (NASDAQ: ACAD) Is An Attractive Pick For Investors Now

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) price closed higher on Friday, July 01, jumping 1.99% above its previous close.

A look at the daily price movement shows that the last close reads $14.09, with intraday deals fluctuated between $13.98 and $14.50. The company’s 5Y monthly beta was ticking 0.52. Taking into account the 52-week price action we note that the stock hit a 52-week high of $28.06 and 52-week low of $12.24. The stock subtracted -11.02% on its value in the past month.

Top 5 Cheap Stocks to Own Right Now

While finding safe stocks with the potential for monster gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Cheap Stock to Own Right Now", we have identified five stocks we believe could appreciate the most even if you just have $1,000 to invest.

Sign up here to get your free report now. .

Sponsored

ACADIA Pharmaceuticals Inc., which has a market valuation of $2.27 billion, is expected to release its quarterly earnings report Feb 22, 2022 – Feb 28, 2022. Analysts tracking ACAD have forecast the quarterly EPS to shrink by -0.24 per share this quarter, while the same analysts predict the annual EPS to hit -$1.4 for the year 2022 and up to -$0.67 for 2023. In this case, analysts estimate an annual EPS growth of -33.30% for the year and 52.10% for the next year.

On average, analysts have forecast the company’s revenue for the quarter will hit $130.84 million, with the likely lows of $126 million and highs of $137 million. The average estimate suggests sales growth for the quarter will likely rise by 4.70% when compared to those recorded in the same quarter in the last financial year. Staying with the analyst view, there is a consensus estimate of $533.09 million for the company’s annual revenue in 2022. Per this projection, the revenue is forecast to grow 10.10% above that which the company brought in 2022.

Revisions to the company’s EPS highlights a short term direction of a stock’s price movement, which in the last 7 days came up with 4 upward and no downward reviews. On the technical perspective front, indicators give ACAD a short term outlook of 100% Sell on average. Looking at the stock’s medium term indicators we note that it is averaging as a 100% Sell, while an average of long term indicators are currently assigning the stock as 50% Sell.

Here is a look at the average analyst rating for the stock as represented on a scale of 1.00 to 5.00, with the extremes of 1.00 and 5.00 suggesting the stock is strong buy or strong sell respectively. Specifically, 20 analysts have assigned ACAD a recommendation rating as follows: 11 rate it as a Hold; 8 advise Buy while 0 analyst(s) assign an Overweight rating. 0 analyst(s) have tagged the ACADIA Pharmaceuticals Inc. (ACAD) stock as Underweight, with 1 recommending Sell. In general, analysts have rated the stock Overweight, a scenario likely to bolster investors out for an opportunity to add to their holdings of the company’s shares.

The overview shows that ACAD’s price is at present -10.94% off the SMA20 and -16.77% from the SMA50. The Relative Strength Index (RSI) metric on the 14-day timeframe is pointing at 42.44, with weekly volatility standing at 4.10%. The indicator jumps to 7.07% when calculated based on the past 30 days. ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)’s beta value is holding at 0.72, while the average true range (ATR) indicator is currently reading 1.30. Considering analysts have assigned the stock a price target range of $10.00-$32.00 as the low and high respectively, we find the trailing 12-month average consensus price target to be $22.47. Based on this estimate, we see that current price is roughly 30.41% off the estimated low and -122.69% off the forecast high. Investors will no doubt be excited to see the share price fall to $20.00, which is the median consensus price, and at that level ACAD would be -39.18% from current price.

Turning out attention to how the ACADIA Pharmaceuticals Inc. stock has performed in comparison to its peers in the industry, here’s what we find: ACAD’s stock is 1.99% on the day and -41.08% in the past 12 months, while Eli Lilly and Company (LLY) traded 0.15% in the last session and was positioned 40.49% up on its price 12 months ago. Another comparison is with Vanda Pharmaceuticals Inc. (VNDA) whose stock price was up 2.66% in the last trading session, and has flourished -47.39% over the past year. Also, Johnson & Johnson (JNJ) showed up trend of 1.13% while its price kept floating at 8.17% over the past year. Elsewhere in the market, the S&P 500 Index has rallied 1.06% in last trading session, with the Dow Jones Industrial also saw a positive session on the day with 1.05%.

An analysis of the ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) stock in terms of its daily trading volume indicates that the 3-month average is 2.65 million.

Current records show that the company has 161.23M in outstanding shares. The insiders’ percentage holdings are 0.10% of outstanding shares while the percentage share held by institutions stands at 92.30%. But the -38.43% downside, the stock’s price has registered year-to-date as of last trading, will likely reignite investor interest given the prospect of it rallying even higher.

Leave a Comment

Your email address will not be published.

[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]
[class^="wpforms-"]